AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Vermont

H0859

An act relating to psychedelic therapy and clinical drug development trials

Status

Pending

2026 Session

IntroducedFeb 3, 2026 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Brian Cina (Democrat)
Type: Clinical Research
Substances: Psilocybin

Official text

Summary (from PoliPsy)

An act relating to psychedelic therapy and clinical drug development trials

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: legislature.vermont.gov

Legislative history

February 3, 2026
Referred
February 3, 2026
Referred
February 3, 2026
Introduced

Loading bill…